Independent RCT and Late-Breaking Science: PMcardio to Take Center Stage at TCT 2025
We’re proud to share that PMcardio and the Queen of Hearts™ (STEMI AI ECG model) will be prominently featured at Transcatheter Cardiovascular Therapeutics (TCT) 2025, the largest interventional cardiology conference in the U.S., taking place October 25–27, 2025 in San Francisco, California.
We’re proud to share that PMcardio and the Queen of Hearts™ (STEMI AI ECG model) will be prominently featured at Transcatheter Cardiovascular Therapeutics (TCT) 2025, the largest interventional cardiology conference in the U.S., taking place October 25–27, 2025 in San Francisco, California.
This year’s program highlights PMcardio’s impact on AI-powered ECG interpretation, cath lab activation, and acute coronary syndrome outcomes, with a Late-Breaking Science presentation in the Main Arena, Best global research World Link Forum and multiple supporting sessions across TCT.
Key studies:
- Featured Best Global Research — DIFFOCULT-3 RCT: A landmark independent, investigator-initiated randomized controlled trial (RCT) of over 6,000 ACS patients across 18 primary PCI centers, comparing PMcardio AI-assisted detection of occlusive myocardial infarction (OMI) with standard care. As the largest RCT of AI in cardiology and emergency medicine to date, its secondary endpoints, including time to intervention, infarct size, and heart function, will be presented at TCT.
- Late-Breaking Science — Queen of Hearts U.S. Registry: A multicenter study across three major U.S. health systems, analyzing over 1,000 STEMI activations. The study evaluates the potential of Queen of Hearts versus standard of care STEMI triage in terms of sensitivity, specificity and false activation rates.
Conference Venue 📍 Moscone Center, located at 747 Howard Street, San Francisco, CA 94103, United States.
Full overview of independent, external and randomized validation studies presented at TCT:
| Name of the presentation | Date, Time & Presenter | Location |
|---|---|---|
| Time for Diagnostic Paradigm Shift from ST-Elevation/Non-ST-Elevation to Occlusive/Non-Occlusive Myocardial Infarction: The DIFOCCULT-3 Trial | 25 October, 2025 5:00 – 5:15 PM Emre Aslanger | Moscone North Exhibition Level Hall E Presentation Theater 4 |
| AI-Powered ECG Interpretation Enables Earlier STEMI Identification and Reduces False Positive Activations in a U.S. Multicenter Registry | 26 October, 2025 8:10 – 8:20 AM Robert Herman | Moscone South Exhibition Level Halls B-C Station 7 |
| AI-Assisted ECG Chest Pain Triage Reduces Time to Reperfusion in STEMI and Improves Short-term Outcomes | 26 October, 2025 10:10 – 10:20 AM Robert Herman | Moscone South Exhibition Level Halls B-C Station 8 |
| Potential Reduction of False Positive STEMI Activations by an Artificial Intelligence ECG Model | 27 October, 2025 2:00 – 2:10 PM Jonathan G. Schwartz | Moscone South Exhibition Level Halls B-C Station 8 |
| Retrospective Assessment of an Artificial Intelligence (AI)-Based ECG Model for Detecting Acute Coronary Occlusion (ACO) in a Diverse Community Hospital Setting | 27 October, 2025 03:20 – 03:30 PM Imran Naeem Aziz | Moscone South Exhibition Level Halls B-C Station 4 |
| Diagnostic Performance of Artificial Intelligence-Powered Electrocardiogram to Detect Acute Coronary Occlusion in Patients with Suspected High-Risk Non-ST Elevation Acute Coronary Syndrome | 27 October, 2025 03:30 – 03:40 PM Pedro E. P. Carvalho | Moscone South Exhibition Level Halls B-C Station 4 |
| PMcardio – Queen of Hearts: AI-Powered ECG Platform for Rapid and Accurate STEMI Triage | 27 October, 2025 4:12 – 4:19 PM Robert Herman | Moscone North Exhibition Level TCT Al Lab |
| Late-Breaking Clinical Science: AI-Enabled ECG Interpretation in STEMI: Findings from a Multicenter U.S. Registry | 28 October, 2025 2:54 – 3:12 PM Tim Henry | Moscone South Exhibition Level Hall A Main Arena |
About TCT Conference
The Transcatheter Cardiovascular Therapeutics (TCT) conference is the largest and most prestigious annual meeting in interventional cardiology, bringing together thousands of clinicians, researchers, industry leaders, and innovators from around the world.
Organized by the Cardiovascular Research Foundation (CRF), TCT has been at the forefront of cardiovascular innovation for over three decades. The meeting serves as the global stage for unveiling groundbreaking research, pivotal clinical trial results, and transformative technologies that are redefining the way cardiovascular disease is diagnosed and treated.
Share this article
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
